Haematology and Leukaemia
Research activity includes acute lymphoblastic leukemia, with studies in Philadelphia chromosome-positive ALL, B-cell precursor ALL, and T-cell ALL. The portfolio also covers relapsed/refractory disease and molecular remission strategies.
- Relapsed/refractory ALL
- CD38-positive T-cell ALL
- Ph-positive ALL
These studies reflect a focus on treatment-resistant blood cancers and precision-directed immunotherapy or targeted therapy combinations.
Oncology and Solid Tumours
The sponsor funds trials in non-small cell lung cancer with EGFR mutation, rectal cancer, anal carcinoma, and glioblastoma. The research landscape includes both locally advanced and recurrent disease settings.
- EGFR-mutated NSCLC
- Rectal cancer
- Anal carcinoma
- Glioblastoma
Key interests include radiochemotherapy, immune checkpoint inhibition, cell-based therapy, and biomarker-guided treatment selection in advanced malignancies.
Cardiovascular Medicine and Inflammation
Clinical research spans chronic heart failure, inflammatory cardiovascular involvement after COVID-19, and post-COVID syndrome. Studies also address myocardial injury and vascular dysfunction linked to systemic inflammation.
- Heart failure with reduced ejection fraction
- COVID-19-related cardiac inflammation
- Post-COVID syndrome
The therapeutic emphasis includes anti-inflammatory treatment, cardiac magnetic resonance imaging-defined disease, and symptom burden such as fatigue and reduced physical function.
Infectious Diseases and Microbiome-Based Therapy
The sponsor supports work on multidrug-resistant Enterobacteriaceae and recurrent urinary tract infections, with an evident interest in fecal microbiota transfer and decolonisation approaches.
- Multidrug-resistant Enterobacteriaceae
- Recurrent urinary tract infection
- Microbiota restoration
These trials explore infection control in resistant bacterial colonisation and prevention of recurrent urogenital infection.
Respiratory and Paediatric Asthma
Research also includes severe asthma exacerbations in preschool asthma, with attention to uncontrolled and partially controlled disease.
- Preschool asthma
- Severe exacerbations
- Airway control
The therapeutic focus is on reducing exacerbation risk and improving control in young children with persistent respiratory disease.
